Shionogi to buy Sciele for $1.4 billion
This article was originally published in Scrip
Executive Summary
Shionogi has signed a definitive agreement to buy the US firm Sciele Pharmafor $1.4 billion. The move aims to boost the mid-sized Japanese firm's presence and marketing capability in the key US market, which it sees as critical to mid-term growth.